Literature DB >> 3589151

Stereoselective serum protein binding of mexiletine enantiomers in man.

K M McErlane, L Igwemezie, C R Kerr.   

Abstract

The binding of mexiletine enantiomers to human serum proteins was studied in vitro using serum samples collected from five healthy male subjects. Racemic mexiletine was added to an aliquot of each subject's serum to cover the concentration range 0.2 to 2.0 micrograms/mL. Following ultrafiltration of the serum samples containing racemic mexiletine, the individual enantiomers were determined using a stereoselective high-performance liquid chromatographic method developed in our laboratory. The assay data thus obtained for the free levels of the enantiomers showed that the free fraction of S(+) mexiletine was 28.32 +/- 1.45% and that of the R(-) enantiomer was 19.80 +/- 1.49%. The binding was shown to be significantly greater (p less than 0.001) for R(-) mexiletine than its antipode. There was no evidence of concentration dependence in binding over the concentration range studied, which covered the normal therapeutic range. However, significant inter-individual variability in the free fractions was observed. The total binding of the enantiomers was 76%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3589151

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  7 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 3.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 4.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

5.  Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains.

Authors:  Da Shi; Yin-xiu Jin; Yi-hong Tang; Hai-hong Hu; Si-yun Xu; Lu-shan Yu; Hui-di Jiang; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

6.  Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias.

Authors:  V L Lanchote; E J Cesarino; V J Santos; A V Moraes Júnior; A M Zanardi; S R Santos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

7.  Chiral Discrimination of Mexiletine Enantiomers by Capillary Electrophoresis Using Cyclodextrins as Chiral Selectors and Experimental Design Method Optimization.

Authors:  Melania Cârcu-Dobrin; Gabriel Hancu; Lajos Attila Papp; Ibolya Fülöp
Journal:  Molecules       Date:  2022-08-31       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.